Reviva Pharmaceuticals Holdings, Inc.

OTC: RVPH · Healthcare · Biotechnology

PublicHQ Cupertino, CA · Santa ClaraCIK 0001742927Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 28DQ —GM —SS 34

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$19.9M

Employees

as of 2026-08-25

Market cap

$6.1M

as of 2026-08-25

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$19.9M-$19.9M2025

Operating income-$20.2M-$20.2M2025

Total assets$15.9M$15.9M2025

Liabilities$7.3M$7.3M2025

Equity$8.6M$8.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Reviva Pharmaceuticals Holdings, Inc.’s financial profile?

Reviva Pharmaceuticals Holdings, Inc. earned -$19.9M in FY2025 net income.

Peers · Healthcare

Kairos Pharma, Ltd.——Eastgate Biotech Corp.——CYduct Diagnostics, Inc.——Medicus Pharma Ltd. Common Stock——Adial Pharmaceuticals, Inc.——Alzamend Neuro Inc——

Neighbors

Santa Clara →

NVIDIA Corporation$215.9B90A Apple Inc.$416.2B84B+Alphabet Inc.$402.8B81B+Broadcom Inc.$63.9B76B+Advanced Micro Devices, Inc.$34.6B78B+Cisco Systems, Inc.$56.7B85A

Key facts

CEOLaxminarayan Bhat

SectorHealthcare

IndustryBiotechnology

HeadquartersCupertino, CA

ExchangeOTC: RVPH

Employees14

IPO date2020-12-15

Latest filings

10-Q2026-08-12 8-K2026-08-12 8-K2026-05-13 10-Q2026-05-13 8-K2026-05-13 8-K2026-04-15 10-K2026-03-30 8-K2026-03-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.